IntelGenx (TSX-V:IGX; OTCQX:IGXT) filed a new non-provisional patent application with the U.S. Patent and Trademark Office, covering a newly developed platform that enables incorporation of oil-based (lipophilic) active ingredients into oral film formulations.
The new platform, suitable for both VersaFilm and VetaFilm, is compatible with several of IntelGenx’s current projects including montelukast, loxapine and cannabis-infused films. The technology may also be used when more than one active ingredient, such as THC and CBD, are applied in a single film product.
“This new filing adds to the global intellectual property estate that we are building for VersaFilm and VetaFilm,” Dr. Horst Zerbe, president and CEO, said in a statement. “We anticipate that this application will also be filed in several other international jurisdictions as the application progresses in the U.S.”
